Mastering the art of patient‑focused treatment
Pipeline/Trials
Our commitment to excellence
Taking on the challenges inherent in today’s cancer treatments isn’t easy…but we’re up for it. We are Athenex—a team of scientists, investigators, and innovators driven by the patients we serve. Our robust investigational pipeline of novel small molecule, biologic, and cellular therapies is focused on both improving outcomes and improving the cancer treatment experience for patients around the world.
Program
Drug candidate
Indication
Pre-clinical
Phase 1
Phase 2
Phase 3
Src Kinase Inhibition
Klisyri® (tirbanibulin ointment)
Actinic keratosis
Oral paclitaxel + encequidar with dostarlimab**
Neoadjuvant breast cancer
(I-SPY 2)
Oral eribulin + encequidar
Solid tumors
Cell Therapy
TCRT-ESO-A2
Multiple tumors
KUR-501 – GD2 autologous CAR-NKT
Neuroblastoma
KUR-502 – CD19 allogeneic CAR-NKT
R/R lymphoma and leukemia
KUR-503 – GPC3 allogeneic CAR-NKT
Hepatocellular Carcinoma
Arginase Deprivation Therapy
PT01
Multiple tumors
Posted pipeline was current on June 28, 2021. Pipeline may not reflect changes in phase of development after June 28, 2021.
* Encequidar is the international nonproprietary name (INN) for HM30181A, our novel P-gp pump inhibitor molecule.
** Collaboration with Quantum Leap Healthcare Collaborative and GlaxoSmithKline.
*** Collaboration with Eli Lilly and Company, makers of ramucirumab.
Clinical Platform
Src Kinase Inhibition
Klisyri® (tirbanibulin ointment)
Actinic keratosis
(FDA APPROVED)
Clinical Platform
Orascovery
Oral paclitaxel + encequidar with dostarlimab**
Neoadjuvant breast cancer
(I-SPY 2)
Oral eribulin + encequidar
Solid tumors
Clinical Platform
Cell Therapy
TCRT-ESO-A2
Multiple tumors
KUR-501 – GD2 autologous CAR-NKT
Neuroblastoma
KUR-502 – CD19 allogeneic CAR-NKT
R/R lymphoma and leukemia
KUR-503 – GPC3 allogeneic CAR-NKT
Hepatocellular Carcinoma
Clinical Platform
Arginase Deprivation Therapy
PT01
Multiple tumors
Posted pipeline was current on June 28, 2021. Pipeline may not reflect changes in phase of development after June 28, 2021.
* Encequidar is the international nonproprietary name (INN) for HM30181A, our novel P-gp pump inhibitor molecule.
** Collaboration with Quantum Leap Healthcare Collaborative and GlaxoSmithKline.
*** Collaboration with Eli Lilly and Company, makers of ramucirumab.